Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis.

ABSTRACT:

Background

Imatinib, a tyrosine kinase inhibitor, has been shown to restore blood-brain barrier integrity and reduce infarct size, haemorrhagic transformation and cerebral oedema in stroke models treated with tissue plasminogen activator. We evaluated the safety of imatinib, based on clinical and neuroradiological data, and its potential influence on neurological and functional outcomes.

Methods

A phase II randomized trial was performed in patients with acute ischaemic stroke treated with intravenous thrombolysis. A total of 60 patients were randomly assigned to four groups [3 (active): 1 (control)]; the active treatment groups received oral imatinib for 6 days at three dose levels (400, 600 and 800 mg). Primary outcome was any adverse event; secondary outcomes were haemorrh

SUBMITTER: Wahlgren N 

PROVIDER: S-EPMC5573589 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature